Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Hims & Hers Health Inc. (NYSE:HIMS) partners with Novo Nordisk to offer affordable weight-loss drug, positioning itself to ...

Novo Nordisk is partnering with online telehealth companies to sell a direct-to-consumer, lower cost version of its popular ...

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Medical pioneers Hims & Hers Health (HIMS) and Novo Nordisk (NVO) are making headlines this week after announcing a partnership to expand obesity care in the telehealth space.

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...